ADMA Biologics Inc vs Howmet Aerospace Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Howmet Aerospace Inc trades at $283 (market cap $112.20B). The key difference: Howmet Aerospace Inc is far larger — about 50.5× ADMA Biologics Inc's market cap, and Howmet Aerospace Inc pays a 0.2% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HWM | |
|---|---|---|
Market Cap | $2.22B | $112.20B |
Sector | Health | Industrials |
52-Week High | $20.38 | $291.28 |
52-Week Low | $7.60 | $171.00 |
Enterprise Value | $2.29B | $116.30B |
Dividend Yield | — | 0.2% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
Howmet Aerospace (HWM) trades at $283.80, up 0.03% today, with a bullish technical signal and strong support at $279. The company reported Q2 2026 EPS of $1.33, beating estimates, and raised full-year guidance due to robust aerospace and defense demand. Revenue grew 24% year-over-year, with a net income margin of 20.52% and ROE of 34.89%.
Outlook is positive with 84% analyst buy ratings and a $334.63 consensus price target, implying 18% upside. Risks include high valuation multiples (P/E 60.63) and capital expenditure increases. Earnings momentum and institutional confidence support further growth, but investors should monitor execution on expanded capacity plans.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →